Virtus ETF Advisers LLC Tcr2 Therapeutics Inc. Transaction History

Virtus ETF Advisers LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $53,869 - $98,095	-11,762 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $5,207 - $11,321	-617 Reduced 4.98%	11,762 $100,000
Q2 2021 Aug 10, 2021	BUY	$16.41 - $24.71 $27,831 - $41,908	1,696 Added 15.88%	12,379 $203,000
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $3,912 - $6,541	192 Added 1.83%	10,683 $236,000
Q4 2020 Feb 12, 2021	BUY	$19.0 - $32.63 $199,329 - $342,321	10,491 New	10,491 $324,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.